Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LMY-920 |
Synonyms | |
Therapy Description |
LMY-920 comprises autologous CD4- and CD8-positive T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing the B-cell activating factor (BAFF) ligand, which potentially induce cytotoxicity against tumor cells expressing BAFF-R (TNFRSF13C), BCMA (TNFRSF17), or TACI (TNFRSF13B) (NCI Drug Dictionary). |